The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

por Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama
Publicado 2019

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor

por Christopher Alvarez-Breckenridge, Julie J. Miller, Naema Nayyar, Corey M. Gill, Andrew Kaneb, Megan D’Andrea, Long P. Le, Jesse Lee, Ju Cheng, Zongli Zheng, William E. Butler, Pratik Multani, Edna Chow Maneval, Sun Ha Paek, Brian D. Toyota, Dora Dias-Santagata, Sandro Santagata, Javier Romero, Alice T. Shaw, Anna F. Farago, Stephen Yip, Daniel P. Cahill, Tracy T. Batchelor, A. John Iafrate, Priscilla K. Brastianos
Publicado 2017